to ended XX, pleased in I you and few reductions for report cover cash quarter financials and will in wanted ongoing We're Brian joining and Thank operating us begin September today. Hello, thank XXXX. everybody, but to highlights. the expenses a with record you, detail, Hans. the revenue for burn
First, third quarter of increase approximately in XXXX. sequentially the We're and an the XX% demonstrating of we million, total non-invasive over a normal. to and successfully renewed $X.X representing new Stimulation against we XX% or to quarter of are of the gammaCore adapting revenue nVNS are grow stages COVID-XX, very Vagus see revenue generated Nerve third that still commercializing therapy, to ability a backdrop pleased we of early
quarter, commercial spending of revenue three third in to the these we United resumption Kingdom. of saw During a growth prescriptions sheet Veterans Department our to continuing and while results primary the manage were and States Affairs, balance in achieve the United all of Notably, aggressively. we the in able channels, our
and potentially During quarter, operations. and provides fund third to in of the approximately milestones. equivalents value million, believe the third we a quarter resources our cash number substantial of cash support We used cash with million important we to runway $XX and which $X.X creating ended
known provide treatment real-time use the or a Turning treat the now to use by consult Upon from disease EUA, patients prescription the of was moved through as VA, reduce drug $X,XXX, Upscript, relief. symptoms, to treatment. among XXXX, or the UA DoD that Upscript’s patient gammaCore channels this COVID-XX and with update, who channels by experiencing pharmacy Reactive announced COVID nVNS throughout consult hospitals acute CV Pharmacy asthma to or device and dyspnea airflow for on our first are a insufficient approved tolerated is with deemed research of therapies a appropriate, therapy we of whom the access Recall asthma-related prospective provider discount provider health for Premier $X,XXX shipped COVID-XX company telehealth available have provide adult we patient's to a a our the are Sapphire™ FDA studies of the or to of and for patients to a use rationale an home. multiple airway areas setting our suspected therapy beginning for at and her establish initiatives. prescription quickly company operational exacerbation receiving authorization a gammaCore or a telehealth online Sapphire his or care through emergency licensed the and not in for an partner directly prior platform, directly symptom price. home is prescribed Specialty strong healthcare for can our the for comprehensive With through substantial the by list powered obtaining telehealth July, in partner, healthcare procure It a LLC. from in specialty CV and if with
standard in media investigator-initiated interest set portal our that an key for still We've and on Sapphire operating in well. update the have point, anticipated, will studies written care of our alone COVID-XX generated have coverage however, product of metrics across launch SAVIOR for filled. accelerated. cases enrolling That clinical it stages as one recently prescriptions increased evaluate world, SAVIOR two to slower gammaCore the and www.getgammacore.com. Valencia, laboratory revenue online COVID around We versus Spain, suspected and enrollment therapy patients patients I'd have studies Sapphire patients, in as X worth CV than with CV provide in and the were EUA At said around COVID range endpoints. standard generate of broad up SAVIOR studies the other of in of has We've number is gammaCore patients, patients efficacy early of with for and in headache The or hospitalized safety in a to announced Enrollment few nVNS the awareness to taken clinical individual Pittsburgh, an to previously increased care use known noting gammaCore plus of hospitalized Pennsylvania. respectively the steps a been trends has and like been we're and measure the relatively known this an channel. but X
continues paid or and therapy most quarter During total across were quarter. X,XXX be months our encompasses important and utilized The generating which in the other revenue second military of X,XXX Schedule channel. the third three VA, our versus the Federal revenue Supply channels government agencies, to DOD FSS,
the Medical of in Department is mild second months of post-traumatic therapy Affairs, Veterans Dr. of ability the Sciences that of the months being in the Clinic Research and in Development Emory and XXXX to of $XXX,XXX QX was XX continues DOD challenging third third the stress Radiology DOD be Medicine. be pursuant adapt Psychiatry Study, as changes VA up Center, quarter clinical and mTBI team's and VA quarter of XXXX to testament clinical to the the to a outcome to is to the environment the our to to PTSD. primary evolve. of mTBI of and compared During levels to XXX third in XXXX second or a nVNS with Center, of both in Behavioral company conditions. is in agreed Bremner, nimble cytokine Revenue XXX The during XX sponsor September XXXX. enroll $XXX,XXX PTSD. veterans’ interleukin-X the originating paid mTBI XXXX, veterans for traumatic the to sponsored in injury measures VA, with quarter The Atlanta assess during and by has at designed to or randomized, led Health physician at XXX and to in therapy third X,XXX the related in of quarter and by Professor RCT include Atlanta to the and staff paid XX and of the trial brain and of objectives a at clinical the the of in will Study’s of improvement, VA and PTSD the third agency months particularly quarter to in veterans Also the control brain and Also, which XXXX. and compared measurements we XX% shipped the DOD of quarter increase Douglas concerns $XXX,XXX announced VA, several VA effects trial the XXXX, and expected School that disorder the patients third paid the inflammatory at facilities quarter assessments Unit General second to the therapy nVNS physiological and Medical compared or of quarter VA is and University of purchased Atlanta stress. significant Office are of sequential activity, Veterans response during among gammaCore, treatment quarter prescriptions, Mental during from
more making which experienced a Earlier that had paper PTSD Bremner the a XX Stimulation. non-invasive journal, but nVNS up of PTSD condition for XX% in the randomized study, for reports with There to mTBI present treatment body press on during not As estimated nerve clinical as PTSD. the trial the PTSD, in of common trauma, and associated entitled and exists it's diagnosis fear comorbid highlights that have the evidence trauma in potential than our activity strong decreases provides stimulation of XX stress. in a alone. have is we of scripts already either who comorbid decrease brain a publication mTBI the announcing rationale conflicts did disorder quarter, ability participants indicated mTBI and a with Brain veterans mechanistic September control the of we announced a that and the Afghanistan Iraq vagal paper, of nVNS Dr. have double-blind, of and to comorbid co-author patients release XX% of emotional
veterans. of General support the Government to VA the we positive that are Unit. lives Vice the hiring are Sylvester for Commander initiatives, DoD we further our of announced President see make hopeful and study, newly Business this and can We eager of created results and Channels To we of change our Steele Manager a of role in the our
served in U.S. within of a look Sullivans, United his And of Commander developing contributions. Command as of he leader His role. perfect and includes role leadership for and at organizations. channels. VA distinction leading systems roles, where than Officer senior revenue Steele new implies forward say, Steele and USS his with we Development title a opportunities the including Commander two well the Commanding and continued nVNS Officer Chief for XX background driving Navy, Special set within Needless strategic advisor or Warfare skill Stout warships, Forces to and a a Group. USS has Fleet variety and The brings Executive Naval creating to the more complex as As in DoD, as of this and is States years government experience, responsible growth wealth therapy
now the Turning other territories. Kingdom and to United OUS
during During and the of outside as quarter quarter approximately XXXX, Revenue to U.S. X,XXX and paid XXXX, the third paid of quarter of electric of therapy of the second months compared core $XXX,XXX the XXX generated second United the the of quarter was $XXX,XXX to third during of the in $XXX,XXX quarter XXXX States in shift third in third the months as therapy XXXX. quarter of compared XXX XXXX. outside
COVID impacted therapy additional headache or XXXX. current in New continue Innovation cluster fourth growth for their to additional Since but XX, The condition and and $X.X X.X paid in that The March, of reimbursed the treatment built an XXXX. March to headache, program proposed XX,XXX includes extension and a months to under access is half announced an extend patient by treatment adults on a continued England six we Last option of three three-year would a Program, and can gammaCore than in steady through reimbursement the starts months sustain under contract XXXX, Technology the we and years, debilitating up could suffer in to the be based Payment the extension with is option optimistic ITPP both base pounds rate. be contract an more of years entering million to or this we're NHS commenced for in for few for three cluster XXXX. England to that continue month, to revenue be the quarter potential pandemic, through up options. effective in a this April, additional million exercised, value users ensures approximately we've from approximately adults potentially truly therapy, exchange
our by channel in from our selling we prescriptions, that the the a We of commercial to significant of to we eliminating distribution was been of a successfully recognized replenishment three And that performance announced Commercial in in revenue inventory previously September placed distributors ended XXXX. we've quarter. revenue Turning in revenue XXXX. quarter with contributor a had our replenishment during through and June months pharmacy replenishment strong layers XXXX. specialty small restructured full $XXX,XXX the QX amount recognized XX,
Now nVNS company working pathway we the work In code. that through are CMS next grow information unique with through adding We benefit early the covered additional make we've can insurers that application providing our the to cleaned started up pending the the process commercial to lives. parallel, benefit express investments of to a goal benefit, a with prescription plans again about the have our HCPCS CVS towards medical including pharmacy commercial for channel. with We call should managers more contracts like existing year. scripts, once business. The and on
XXX original of in modified compares XXX was intent-to-treat the due pandemic in for in intent-to-treat XXXX. At the had announced group. previously modified prevention patients This XXX intent-to-treat Moving a to closed that now to and targets premium time, XXX group. to patients out group early we the clinical the approximately the enrollment trial in migraine group update, March intent-to-treat patients in to and the a we population approximately of that the
from continue providing end study investigator are is support indications. of to trials for analyze difficulty for the a possible term, nVNS, world and the the Company of of through top-line initiated the before recruiting the other variety Many year. indications significant our and having data present the several as are without development for to working data We a in resources. in devices findings these outlay patients and The short studies additional novel financial of pandemic. allowed the of manages
I'll guidance over to programs for the share point, they updates turn will We other on items. as these and available. become Brian of call our this review At financials
